Borviz 2.5 Mg Injection

Borviz 2.5 Mg Injection Specification

Dosage Form
Injection

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Salt Composition
Bortezomib 2.5 mg

Enzyme Types
Proteasome Inhibitor

Feature
Lyophilized powder for reconstitution, single-use vial

Ingredients
Bortezomib

Application
Hospital, Clinical use, Cancer Treatment

Physical Color/Texture
Tan liquid

Fermentation Smell
Normal Smell

Enzymatic Activity
Inhibits 26S proteasome activity

Storage Instructions
Dry place

Shelf Life
upto 24 Days

Prescription Required
Yes

Concentration
2.5 mg per vial

Diluent Required
Sterile water for injection

Administration Route
Intravenous or Subcutaneous

Compatibility
Do not mix with other drugs in same solution

Marketed By
Intas Pharmaceuticals Ltd.

USP
High purity, Stable formulation, WHO GMP certified manufacturing

Packaging Type
Vial with carton

Pack Size
Single-use vial

Borviz 2.5 Mg Injection Trade Information

Minimum Order Quantity
1 Unit

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Units Per Month

Delivery Time
7-10 Seconds

Main Export Market(s)
Asia, Australia, North America, Eastern Europe, Western Europe

Main Domestic Market
All India

About Borviz 2.5 Mg Injection

Order Borviz 2.5 Mg Injection-potent, meticulously formulated for hospital and clinical use. Manufactured by Intas Pharmaceuticals Ltd., this high-purity product arrives fresh in a tamper-proof vial and carton, ready for reconstitution with sterile water. Bortezomib, as a redoubtable proteasome inhibitor, offers breathtaking efficacy for multiple myeloma and mantle cell lymphoma treatments. Buy with confidence from India's WHO GMP certified exporter and wholesaler. Designed for single-use with intravenous or subcutaneous administration, Borviz provides stable, reliable cancer therapy, with each tan-colored liquid vial containing 2.5 mg concentration.

Unmatched Cancer Therapy for Professionals

Borviz 2.5 Mg Injection is widely used by oncologists and hematologists in the treatment of multiple myeloma and mantle cell lymphoma. Its lyophilized powder form ensures stable reconstitution, while WHO GMP certified manufacturing guarantees uncompromising quality. The single-use vial ensures each preparation remains uncontaminated. As a competitive advantage, Borviz's potent Bortezomib action delivers clinically proven outcomes, meeting stringent regulatory requirements for hospital and clinical use worldwide.

Reliable Delivery and Order Fulfilment

Borviz 2.5 Mg Injection is supplied efficiently with careful handling, ensuring the product is handed over within the specified timeline. The delivery time relies on your region, but prompt exchange and secure shipment guarantee freshness upon order completion. With substantial supply ability, bulk orders are accommodated for hospitals and clinics. Payment terms are flexible, supporting bank transfers or advance payments for smooth procurement, further strengthening our commitment to swift, dependable service.

Specification

Country of Origin	Made in India
Form	Injection
Packaging Size	2.5 mg in a Vial
Prescription/Non prescription	Prescription
Treatment	Multiple myeloma Mantle-cell lymphoma
Composition	Bortezomib (2.5mg)

FAQ's of Borviz 2.5 Mg Injection:

Q: How should Borviz 2.5 Mg Injection be administered?

A: Borviz 2.5 Mg Injection must be administered either intravenously or subcutaneously by a qualified healthcare professional, following dilution with sterile water for injection. It is essential not to mix it with other drugs in the same solution.

Q: What are the main indications for using this injection?

A: Borviz 2.5 Mg Injection is mainly indicated for the treatment of multiple myeloma and mantle cell lymphoma, as prescribed by a physician experienced in cancer therapies.

Q: When is the injection prepared and how should it be stored?

A: The injection is freshly prepared just before administration. It should be stored in a dry place, and the reconstituted solution, once prepared, must be used immediately or as per healthcare provider's instructions. The shelf life of the unopened vial is up to 24 days.

Q: Where is Borviz 2.5 Mg Injection manufactured and what are its quality certifications?

A: This product is made in India by Intas Pharmaceuticals Ltd., and it is manufactured in WHO GMP certified facilities to ensure the highest standards of safety and quality.

Q: What is the reconstitution process for Borviz 2.5 Mg Injection?

A: Reconstitution involves adding sterile water for injection into the single-use vial containing lyophilized powder, following aseptic techniques. The dissolved solution should be inspected for particulates before administration.

Q: What are the benefits of using Borviz 2.5 Mg Injection over other formulations?

A: Borviz offers high purity, a stable formulation, and a breathtakingly potent enzymatic action against cancer cells. Its competitive advantage lies in single-use packaging, reliable supply, and regulatory compliance for international markets.